A Preliminary Pharmacogenetic Investigation of Adverse Events From Topiramate in Heavy Drinkers

Experimental and Clinical Psychopharmacology

Volumn 17, Issue 2, 2009, Pages 122-129

  Ray, Lara A ^a,b   Miranda Jr , Robert ^b   MacKillop, James ^a,c   McGeary, John ^a,d   Tidey, Jennifer W ^b   Rohsenow, Damaris J ^a,d   Gwaltney, Chad ^b   Swift, Robert W ^a,d   Monti, Peter M ^a,d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

alcohol; glutamate; pharmacogenetics; side effects; topiramate

Indexed keywords

GLUTAMATE RECEPTOR 5; GLUTAMIC ACID; TOPIRAMATE;

ADULT; ALCOHOLISM; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; GRIK1 GENE; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NERVOUSNESS; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; PARESTHESIA; PHARMACOGENETICS; PREDICTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WORD FINDING DIFFICULTY;

ADULT; ALCOHOLISM; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, KAINIC ACID; SEVERITY OF ILLNESS INDEX;

EID: 65249152974     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0015700     Document Type: Article

References (38)

1. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 65 (2008) 135-144
2. Barbon A., and Barlati S. Genomic organization, proposed alternative splicing mechanisms, and RNA editing structure of GRIK1. Cytogenetics and Cell Genetics 88 (2000) 236-239
3. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
4. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences, USA 95 (1998) 9608-9613
5. Dar R., Serlin R.C., and Omer H. Misuse of statistical tests in three decades of psychotherapy research. Journal of Consulting and Clinical Psychology 62 (1994) 75-82
6. Dodd P.R., Beckmann A.M., Davidson M.S., and Wilce P.A. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochemistry International 37 (2000) 509-533
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient ed. (SCID-I/P, version 2.0) (1995), Biometrics Research Department, New York State Psychiatric Institute, New York
8. Flannery B.A., Allen J.P., Pettinati H.M., Rohsenow D.J., Cisler R.A., and Litten R.Z. Using acquired knowledge and new technologies in alcoholism treatment trials. Alcoholism: Clinical and Experimental Research 26 (2002) 423-429
9. Freeman B., Powell J., Ball D., Hill L., Craig I., and Plomin R. DNA by mail: An inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behavior Genetics 27 (1997) 251-257
10. Fritz N., Glogau S., Hoffmann J., Rademacher M., Elger C.E., and Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior 6 (2005) 373-381
11. Goldstein D.B., Need A.C., Singh R., and Sisodiya S.M. Potential genetic causes of heterogeneity of treatment effects. American Journal of Medicine 120 4, Suppl. 1 (2007) S21-S25
12. Gryder D.S., and Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. Journal of Neuroscience 23 (2003) 7069-7074
13. Hyman S.E., and Malenka R.C. Addiction and the brain: The neurobiology of compulsion and its persistence. Nature Reviews Neuroscience 2 (2001) 695-703
14. Johnson B.A. Recent advances in the development of treatments for alcohol and cocaine dependence: Focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 19 (2005) 873-896
15. Johnson B.A., and Ait-Daoud N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharmacology (Berlin) 149 (2000) 327-344
16. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 361 (2003, May 17) 1677-1685
17. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA 298 (2007, October 10) 1641-1651
18. Johnson B.A., Swift R.M., Addolorato G., Ciraulo D.A., and Myrick H. Safety and efficacy of GABAergic medications for treating alcoholism. Alcoholism: Clinical and Experimental Research 29 (2005) 248-254
19. Kaminski R.M., Banerjee M., and Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 (2004) 1097-1104
20. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 9 (2004) 442-473
21. Kranzler H.R., Covault J., Herman A., Burian L., and Arias A. Glutamate receptor gene variation and alcohol dependence risk. Alcoholism: Clinical and Experimental Research 31 (2007) 71A
22. Krupitsky E.M., Rudenko A.A., Burakov A.M., Slavina T.Y., Grinenko A.A., Pittman B., et al. Antiglutamatergic strategies for ethanol detoxification: Comparison with placebo and diazepam. Alcoholism: Clinical and Experimental Research 31 (2007) 604-611
23. Lench N., Stanier P., and Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet 1 (1988, June 18) 1356-1358
24. Lipsky R.H., and Goldman D. Genomics and variation of ionotropic glutamate receptors. Annals of the New York Academy of Sciences 1003 (2003) 22-35
25. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health & Research World 22 1 (1998) 13-24
26. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genetic Analysis 14 (1999) 143-149
27. Miranda Jr. R., MacKillop J., Monti P.M., Rohsenow D.J., Tidey J., Gwaltney C., et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: A preliminary laboratory study. Alcoholism: Clinical and Experimental Research 32 (2008) 489-497
28. O'Brien C.P. Prospects for a genomic approach to the treatment of alcoholism. Archives of General Psychiatry 65 (2008) 132-133
29. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28 (2003) 1546-1552
30. Raguraman J., Priyadharshini R.K., and Chandrasekaran R. Effects of topiramate in alcohol dependence. Australian and New Zealand Journal of Psychiatry 39 (2005) 736-737
31. Ray L.A., and Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Archives of General Psychiatry 64 (2007) 1069-1077
32. Rubio G., Ponce G., Jimenez-Arriero M.A., Palomo T., Manzanares J., and Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37 (2004) 37-40
33. Sobell L.C., Maisto S.A., Sobell M.B., and Cooper A.M. Reliability of alcohol abusers' self-reports of drinking behavior. Behaviour Research and Therapy 17 (1979) 157-160
34. Spitz E., Moutier R., Reed T., Busnel M.C., Marchaland C., Roubertoux P.L., et al. Comparative diagnoses of twin zygosity by SSLP variant analysis, questionnaire, and dermatoglyphic analysis. Behavior Genetics 26 1 (1996) 55-63
35. Thompson P.J., Baxendale S.A., Duncan J.S., and Sander J.W. Effects of topiramate on cognitive function. Journal of Neurology, Neurosurgery and Psychiatry 69 (2000) 636-641
36. Walker A.H., Najarian D., White D.L., Jaffe J.F., Kanetsky P.A., and Rebbeck T.R. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environmental Health Perspectives 107 (1999) 517-520
37. Weiss F., Lorang M.T., Bloom F.E., and Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: Genetic and motivational determinants. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 250-258
38. Weiss F., and Porrino L.J. Behavioral neurobiology of alcohol addiction: Recent advances and challenges. Journal of Neuroscience 22 (2002) 3332-3337